Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial.

PloS One
Chris FoxGill Livingston

Abstract

Agitation in Alzheimer's disease (AD) is common and associated with poor patient life-quality and carer distress. The best evidence-based pharmacological treatments are antipsychotics which have limited benefits with increased morbidity and mortality. There are no memantine trials in clinically significant agitation but post-hoc analyses in other populations found reduced agitation. We tested the primary hypothesis, memantine is superior to placebo for clinically significant agitation, in patients with moderate-to-severe AD. We recruited 153 participants with AD and clinically significant agitation from care-homes or hospitals for a double-blind randomised-controlled trial and 149 people started the trial of memantine versus placebo. The primary outcome was 6 weeks mixed model autoregressive analysis of Cohen-Mansfield Agitation Inventory (CMAI). Secondary outcomes were: 12 weeks CMAI; 6 and 12 weeks Neuropsychiatric symptoms (NPI), Clinical Global Impression Change (CGI-C), Standardised Mini Mental State Examination, Severe Impairment Battery. Using a mixed effects model we found no significant differences in the primary outcome, 6 weeks CMAI, between memantine and placebo (memantine lower -3.0; -8.3 to 2.2, p = 0.26); or 12 w...Continue Reading

Associated Clinical Trials

References

Sep 1, 1975·Archives of Neurology·V C HachinskiL Symon
May 1, 1989·Journal of Gerontology·J Cohen-MansfieldA S Rosenthal
Oct 1, 1986·Journal of the American Geriatrics Society·J Cohen-Mansfield, N Billig
Nov 3, 2005·The American Journal of Psychiatry·Gill LivingstonUNKNOWN Old Age Task Force of the World Federation of Biological Psychiatry
Dec 20, 2005·Lancet·Cleusa P FerriUNKNOWN Alzheimer's Disease International
Mar 1, 2006·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Lon S SchneiderPhilip S Insel
May 23, 2006·Nature Reviews. Neuroscience·Clive Ballard, Robert Howard
Oct 5, 2007·The New England Journal of Medicine·Robert J HowardUNKNOWN CALM-AD Trial Group
Dec 7, 2007·The Annals of Pharmacotherapy·Ian D MaidmentCornelius L Katona
Nov 8, 2008·Health and Quality of Life Outcomes·Maria FerraraClaudia Bauco
Jul 28, 2009·Acta Biomaterialia·A PatlollaT Livingston Arinzeh
Sep 18, 2010·International Journal of Geriatric Psychiatry·Robert HowardRichard Gray

❮ Previous
Next ❯

Citations

Jan 23, 2014·Postgraduate Medical Journal·Barnabas James Gilbert
Oct 5, 2013·Current Translational Geriatrics and Experimental Gerontology Reports·Lawrence S Honig, Clara D Boyd
Jan 10, 2013·The Journal of Nutrition, Health & Aging·J E Morley
Mar 27, 2013·Current Opinion in Psychiatry·Clive Ballard, Anne Corbett
Nov 26, 2015·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Andreas StröhleNina Rieckmann
May 15, 2015·Neurology·Geke A H van den ElsenMarcel G M Olde Rikkert
Feb 26, 2015·Neurodegenerative Disease Management·Damien Gallagher, Nathan Herrmann
Dec 3, 2014·The British Journal of Psychiatry : the Journal of Mental Science·Gill LivingstonClaudia Cooper
Jul 28, 2016·Expert Opinion on Pharmacotherapy·William James Deardorff, George T Grossberg
Oct 13, 2014·Journal of the American Medical Directors Association·Byron CreeseClive Ballard
May 17, 2018·Expert Review of Neurotherapeutics·Byron CreeseClive Ballard
Dec 30, 2014·World Journal of Psychiatry·Subramoniam Madhusoodanan, Mark Bryan Ting
May 15, 2015·The Cochrane Database of Systematic Reviews·Richard BrownElizabeth L Sampson
Apr 11, 2018·British Journal of Clinical Pharmacology·Khachen KongpakwattanaNathorn Chaiyakunapruk
Aug 26, 2015·International Psychogeriatrics·Paul B RosenbergUNKNOWN CitAD Research Group
Dec 22, 2012·International Psychogeriatrics·Paula T TrzepaczConstantine Lyketsos
Apr 23, 2015·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Jue Jiang, Hong Jiang
Jun 25, 2019·Current Treatment Options in Neurology·John M Ringman, Lon Schneider
May 31, 2014·Journal of Neurology, Neurosurgery, and Psychiatry·Jun WangLan Tan
Mar 20, 2015·Clinical Pharmacology and Therapeutics·Aia AhmedMgm Olde Rikkert
Apr 24, 2016·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Heii AraiUNKNOWN J-CATIA Study Group
Jun 25, 2016·Journal of the American Geriatrics Society·Daniela KollerJulie P W Bynum
May 18, 2019·Drugs in R&D·Stephanie V PhanSusan C Fagan
Aug 7, 2017·Therapeutic Advances in Neurological Disorders·Olivier Pierre TibleArmin von Gunten
Mar 21, 2019·The Cochrane Database of Systematic Reviews·Rupert McShaneJean Debarros
Mar 26, 2013·Journal of Clinical Pathology·Barnabas James Gilbert
Feb 28, 2018·Frontiers in Aging Neuroscience·Devesh TewariAtanas G Atanasov
Sep 19, 2017·Journal of Alzheimer's Disease : JAD·Taro KishiNakao Iwata
Feb 26, 2019·Frontiers in Neuroscience·Jinping LiuYan Wu
Jan 29, 2019·Journal of Alzheimer's Disease : JAD·Jeffrey L CummingsClive Ballard
Oct 6, 2017·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·E E Vasenina, O A Gan'kina
Jan 7, 2019·European Journal of Clinical Pharmacology·Ningyuan ZhangQingshan Zheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here